Glofitamab for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma
Clinical trial NCT06956092 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06956092
- Sponsor
- Zhengzhou University
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2025-05-30
- Primary completion
- 2028-06-01
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.